News and Trends 18 Mar 2019
Shares Drop 40% as Allergy Therapeutics Announces Failed Phase III Trial
Allergy Therapeutics has revealed that its immunotherapy for birch pollen allergy did not result in a significant symptom improvement when compared to a placebo. As a direct result of the announcement, the shares of Allergy Therapeutics on the London Stock Exchange dropped over 40% within two hours. The phase III trial enrolled 582 people across […]